The Risk of Congestive Heart Failure: Sobering Lessons from the Framingham Heart Study

Overview

Journal Curr Cardiol Rep

Publisher Current Science

Specialty Cardiology & Vascular Diseases

Date 2001 Apr 18

PMID 11305971

Citations 19

Authors

D M Lloyd-Jones

Affiliations

Soon will be listed here.

Abstract

This review highlights recent contributions of the Framingham Heart Study to our understanding of the epidemiology of congestive heart failure (CHF). Given its uniform criteria for the diagnosis of CHF and its long duration of follow-up, the Framingham study has had a unique perspective on the short- and long-term risk of developing CHF, its predisposing risk factors, and its prognosis in a general, community-based population. Some recent studies from Framingham have provided important insights on CHF: the lifetime risk is estimated to be 20% for men and women; hypertension is the most important modifiable risk factor, with a population-attributable risk of CHF of 59% for women and 39% for men; a clinical prediction rule for development of CHF has recently been published; and the prognosis after development of CHF is grim, with a median survival of 1.7 years in men and 3.2 years in women.

Citing Articles

Certain beta blockers (e.g., bisoprolol) may be reevaluated in hypertension guidelines for patients with left ventricular hypertrophy to diminish the ventricular arrhythmic risk.

Koracevic G, Stojanovic M, Lovic D, Zdravkovic M, Sakac D J Hum Hypertens. 2021; 35(7):564-576.

PMID: 33654234 DOI: 10.1038/s41371-021-00505-8.

The Utilization of Spironolactone in Heart Failure Patients at a Tertiary Hospital in Saudi Arabia.

Alotaibi A, Alabdan N, Alotaibi A, Aljaafary H, Alqahtani M Cureus. 2020; 12(8):e10032.

PMID: 32983725 PMC: 7515793. DOI: 10.7759/cureus.10032.

Muscle-Powered Counterpulsation for Untethered, Non-Blood-Contacting Cardiac Support: A Path to Destination Therapy.

Han J, Aranda-Michel E, Trumble D IEEE Trans Biomed Eng. 2020; 67(11):3035-3047.

PMID: 32086191 PMC: 7587079. DOI: 10.1109/TBME.2020.2974826.

The Effects of Bradykinin B1 Receptor Antagonism on the Myocardial and Vascular Consequences of Hypertension in SHR Rats.

Deres L, Eros K, Horvath O, Bencze N, Cseko C, Farkas S Front Physiol. 2019; 10:624.

PMID: 31178756 PMC: 6537226. DOI: 10.3389/fphys.2019.00624.

Relation between plasma phospholipid oleic acid and risk of heart failure.

Morin S, Gaziano J, Djousse L Eur J Nutr. 2017; 57(8):2937-2942.

PMID: 29094199 PMC: 6519072. DOI: 10.1007/s00394-017-1565-1.

References

Senni M, Tribouilloy C, Rodeheffer R, Jacobsen S, Evans J, Bailey K . Congestive heart failure in the community: trends in incidence and survival in a 10-year period. Arch Intern Med. 1999; 159(1):29-34. DOI: 10.1001/archinte.159.1.29. View

Ho K, Pinsky J, Kannel W, Levy D . The epidemiology of heart failure: the Framingham Study. J Am Coll Cardiol. 1993; 22(4 Suppl A):6A-13A. DOI: 10.1016/0735-1097(93)90455-a. View

Remes J, Reunanen A, Aromaa A, Pyorala K . Incidence of heart failure in eastern Finland: a population-based surveillance study. Eur Heart J. 1992; 13(5):588-93. DOI: 10.1093/oxfordjournals.eurheartj.a060220. View

Kannel W . Epidemiological aspects of heart failure. Cardiol Clin. 1989; 7(1):1-9. View

Vasan R, Larson M, Benjamin E, Evans J, Levy D . Left ventricular dilatation and the risk of congestive heart failure in people without myocardial infarction. N Engl J Med. 1997; 336(19):1350-5. DOI: 10.1056/NEJM199705083361903. View

Senni M, Tribouilloy C, Rodeheffer R, Jacobsen S, Evans J, Bailey K . Congestive heart failure in the community: a study of all incident cases in Olmsted County, Minnesota, in 1991. Circulation. 1998; 98(21):2282-9. DOI: 10.1161/01.cir.98.21.2282. View

Freed L, Levy D, Levine R, Larson M, Evans J, FULLER D . Prevalence and clinical outcome of mitral-valve prolapse. N Engl J Med. 1999; 341(1):1-7. DOI: 10.1056/NEJM199907013410101. View

Kannel W, DAgostino R, Silbershatz H, Belanger A, Wilson P, Levy D . Profile for estimating risk of heart failure. Arch Intern Med. 1999; 159(11):1197-204. DOI: 10.1001/archinte.159.11.1197. View

Vasan R, Larson M, Benjamin E, Evans J, Reiss C, Levy D . Congestive heart failure in subjects with normal versus reduced left ventricular ejection fraction: prevalence and mortality in a population-based cohort. J Am Coll Cardiol. 1999; 33(7):1948-55. DOI: 10.1016/s0735-1097(99)00118-7. View

10.

Ho K, Anderson K, Kannel W, Grossman W, Levy D . Survival after the onset of congestive heart failure in Framingham Heart Study subjects. Circulation. 1993; 88(1):107-15. DOI: 10.1161/01.cir.88.1.107. View

11.

Galderisi M, Anderson K, Wilson P, Levy D . Echocardiographic evidence for the existence of a distinct diabetic cardiomyopathy (the Framingham Heart Study). Am J Cardiol. 1991; 68(1):85-9. DOI: 10.1016/0002-9149(91)90716-x. View

12.

Lloyd-Jones D, Larson M, Beiser A, Levy D . Lifetime risk of developing coronary heart disease. Lancet. 1999; 353(9147):89-92. DOI: 10.1016/S0140-6736(98)10279-9. View

13.

Braunwald E . Shattuck lecture--cardiovascular medicine at the turn of the millennium: triumphs, concerns, and opportunities. N Engl J Med. 1997; 337(19):1360-9. DOI: 10.1056/NEJM199711063371906. View

14.

McKee P, CASTELLI W, MCNAMARA P, Kannel W . The natural history of congestive heart failure: the Framingham study. N Engl J Med. 1971; 285(26):1441-6. DOI: 10.1056/NEJM197112232852601. View

15.

Levy D, Larson M, Vasan R, Kannel W, Ho K . The progression from hypertension to congestive heart failure. JAMA. 1996; 275(20):1557-62. View

16.

Seshadri S, Wolf P, Beiser A, Au R, McNulty K, White R . Lifetime risk of dementia and Alzheimer's disease. The impact of mortality on risk estimates in the Framingham Study. Neurology. 1997; 49(6):1498-504. DOI: 10.1212/wnl.49.6.1498. View

17.

Goldberg R, Konstam M . Assessing the population burden from heart failure: need for sentinel population-based surveillance systems. Arch Intern Med. 1999; 159(1):15-7. DOI: 10.1001/archinte.159.1.15. View